# Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

> **NCT00806767** · PHASE2 · COMPLETED · sponsor: **Institut Paoli-Calmettes** · enrollment: 82 (estimated)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **BIOLOGICAL:** therapeutic immune globulin
- **DRUG:** busulfan
- **DRUG:** fludarabine phosphate
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00806767
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806767, "Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00806767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*